- Home
- CING vs KZR Comparison
CING vs KZR Comparison
Compare CING & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CING
- KZR
- Stock Information
- Founded
- CING 2012
- KZR 2015
- Country
- CING United States
- KZR United States
- Employees
- CING N/A
- KZR N/A
- Industry
- CING Biotechnology: Pharmaceutical Preparations
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- CING Health Care
- KZR Health Care
- Exchange
- CING Nasdaq
- KZR Nasdaq
- Market Cap
- CING 26.7M
- KZR 29.7M
- IPO Year
- CING 2021
- KZR 2018
- Fundamental
- Price
- CING $3.86
- KZR $4.02
- Analyst Decision
- CING Strong Buy
- KZR Hold
- Analyst Count
- CING 4
- KZR 2
- Target Price
- CING $31.00
- KZR $9.00
- AVG Volume (30 Days)
- CING 153.1K
- KZR 38.1K
- Earning Date
- CING 11-06-2025
- KZR 08-13-2025
- Dividend Yield
- CING N/A
- KZR N/A
- EPS Growth
- CING N/A
- KZR N/A
- EPS
- CING N/A
- KZR N/A
- Revenue
- CING N/A
- KZR N/A
- Revenue This Year
- CING N/A
- KZR N/A
- Revenue Next Year
- CING N/A
- KZR N/A
- P/E Ratio
- CING N/A
- KZR N/A
- Revenue Growth
- CING N/A
- KZR N/A
- 52 Week Low
- CING $3.02
- KZR $3.62
- 52 Week High
- CING $7.00
- KZR $9.18
- Technical
- Relative Strength Index (RSI)
- CING 43.49
- KZR 50.04
- Support Level
- CING $3.61
- KZR $3.76
- Resistance Level
- CING $4.12
- KZR $4.15
- Average True Range (ATR)
- CING 0.25
- KZR 0.15
- MACD
- CING 0.00
- KZR 0.03
- Stochastic Oscillator
- CING 30.91
- KZR 57.78
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.